Claims
- 1. A pharmaceutical composition useful in the treatment of edema and hypertension which also maintains uric acid at pretreatment levels or causes a decrease in uric acid in patients which comprises along with a pharmaceutically acceptable carrier 50 mg. to 500 mg. of a compound of the formula: ##SPC15##
- wherein
- A is oxygen;
- R is lower alkyl having from 1 to 5 carbon atoms, cycloalkyl, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo,
- R.sup.1 is hydrogen, lower alkyl having 1 to 5 carbon atoms, lower alkenyl having 3 to 5 carbon atoms, lower alkynyl having from 3 to 5 carbon atoms, phenyl lower alkyl wherein lower alkyl has 1 to 3 carbon atoms, phenyl lower alkenyl wherein lower alkenyl has 2 to 5 carbon atoms, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo;
- X.sup.1 is hydrogen, methyl or halo; and
- X.sup.2 is methyl or halo; and
- Y is alkylene or haloalkylene containing a maximum of 4 carbon atoms, and
- the racemic form, the enantiomers and the non-toxic, pharmacologically acceptable salt thereof.
- 2. A method for the treatment of edema and hypertension which comprises administering to a patient in need of said treatment a unitary dosage of from 50 mg. to 500 mg. of a compound of the formula: ##SPC16##
- wherein
- A is oxygen;
- R is lower alkyl having from 1 to 5 carbon atoms, cycloalkyl, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo;
- R.sup.1 is hydrogen, lower alkyl having 1 to 5 carbon atoms, lower alkenyl having 3 to 5 carbon atoms, lower alkynyl having from 3 to 5 carbon atoms, phenyl lower alkyl wherein lower alkyl has 1 to 3 carbon atoms, phenyl lower alkenyl wherein the lower alkenyl has 2 to 5 carbon atoms, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo;
- X.sup.1 is hydrogen, methyl or halo; and
- X.sup.2 is methyl or halo; and
- Y is alkylene or haloalkylene containing a maximum of 4 carbon atoms, and
- the racemic form, the enantiomers and the non-toxic, pharmacologically acceptable salt thereof.
- 3. The pharmaceutical composition of claim 1 wherein the compound is (1,3-dioxo-2-cyclopentyl, 2,5-dimethyl-4-chloro-6-indanyloxy)acetic acid.
- 4. The method of treatment of claim 2 wherein the compound to be administered is (1,3-dioxo-2-cyclopentyl-2,5-dimethyl-4-chloro-6-indanyloxy)acetic acid.
Parent Case Info
This application is a continuation-in-part of our co-pending application Ser. No. 405,967 filed Oct. 12, 1973.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3704314 |
Cragoe, Jr. |
Nov 1972 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
405967 |
Oct 1973 |
|